Rentschler Development Services

At Rentschler Biopharma, we are committed to being your strategic partner, providing not just solutions but also expert support that empowers your success and contribution to the treatment of serious and rare diseases. We recognize the importance of providing our clients with the best-fit solution to realizing their ideas and projects. Our Rentschler Development Services Program is a comprehensive framework aimed at tailoring development projects to clients’ particular needs and project stages.

OPC 150211 0048 1 2000L Xcellerex Single Use

The best-fit solution for your endeavor

Our goal is to empower clients by offering a range of tailored services. Whether you’re a startup or an established player, we understand that one size does not fit all. With the Development Services Program, you can choose from three different options: Velocity, Flexibility, and Liberty.

Velocity is our fast-track service offering for clients who must be fast. With our fixed timelines, fixed prices and standardized processes, we reliably deliver released Drug Substance for your clinical Phase I/II project on-time.

Find out more

Sometimes clients require flexibility due to shifting priorities, unforeseen challenges, or changing market dynamics. Flexibility provides you with customized timelines and ensures that you can pivot, when necessary, without compromising quality independent of the clinical phase.

Find out more

For clients who thrive on experimentation and innovation, Liberty offers standalone activities and work packages to test hypotheses, fill a specific gap in their portfolio, iterate rapidly, and stay ahead of the wave.

Find out more

Our Track Record - Reliability you can trust

Over

180

biotherapeutics, supported by full-service solutions

100+

successful submissions for clinical trials

More than

50%

of biotherapeutics are complex proteins such as advanced antibody formats and recombinant enzymes

active commercialized products with marketing approvals in over 30 countries

Contribution to nearly

25%

of FDA-approved biopharmaceuticals in 2023

More than

years of experience developing, establishing, and qualifying analytical methods

Get in Touch with our Business Development Team

Are you interested in learning more? We look forward to hearing from you!

This field is required

Please enter a valid e-mail address

*Required Fields

I have acknowledged the information regarding Data Protection . I agree that my details and data will be collected and stored electronically to respond to my inquiry. You can revoke your consent at any time for the future by sending an email to datenschutz@rentschler-biopharma.com .

This field is required